You are here

ASIA CHOICES CHampix (Varenicline) Observational Investigation in the CEssation of Smoking

Last updated on December 5, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Beijing, Beijing, 100029 China
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Smoking Cessation
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- All patients enrolled should meet the usual prescribing criteria for Champix® as per
the local product information and should be entered into the trial at the
investigator's discretion

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- All patients enrolled should meet the usual prescribing criteria for Champix® as per
the local product information and should be entered into the trial at the
investigator's discretion

NCT00808015
Pfizer
Completed
ASIA CHOICES CHampix (Varenicline) Observational Investigation in the CEssation of Smoking

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
ASIA CHOICES CHampix (Varenicline) Observational Investigation in the CEssation of Smoking
ASIA CHOICES CHampix Observational Investigation in the CEssation of Smoking
The purpose of this study is to describe the characteristics of the smoker who wants to quit and his/her treating physician, in addition to determine the safety and effectiveness of Champix in the real-world setting of smokers in routine clinical practice.
Sampling Method Description: Patients enrolled after being prescribed Champix for smoking cessation at the sole discretion of treating physician and patient.
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
This study is in Asian patients. The patients enrolled should be of legal adult age who regularly smoke and whose main tobacco product is cigarettes. The patients must be willing to make an attempt to stop smoking.
Smoking Cessation
Drug: varenicline
Champix will be prescribed as per usual practice and at the sole discretion of the physician
Other Name: Champix, Chantix
Patients in routine practice
Patients prescribed Champix by treating physician and then entered into trial
Intervention: Drug: varenicline
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1373
July 2010
July 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • All patients enrolled should meet the usual prescribing criteria for Champix® as per the local product information and should be entered into the trial at the investigator's discretion

Exclusion Criteria:

  • All patients enrolled should meet the usual prescribing criteria for Champix® as per the local product information and should be entered into the trial at the investigator's discretion
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
China,   India,   Korea, Republic of,   Philippines
 
 
NCT00808015
A3051112
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
April 2015

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now